Amgen's earnings call highlighted a strong performance and a confident outlook.  The company announced a large share repurchase program, a settlement related to past sales and marketing practices, and raised its 2011 revenue and EPS guidance.  Management's tone was optimistic, citing strong growth in various product lines, particularly outside of ESAs, and continued progress in their pipeline.
[2]
